Seeking Alpha
 

Sanofi (SNYNF)

- OTCQB
  • Oct. 28, 2014, 9:14 AM
    • Sanofi (NYSE:SNY) (OTCQB:SNYNF) Q3 results (€M): Total Revenues: 8,781 (+4.1%); Diabetes: 1,799 (+8.3%); Vaccines: 1,451 (+11.2%); Consumer Healthcare: 819 (+12.9%); Genzyme: 649 (+24.6%); Animal Health: 515 (+12.7); Gross Profit: 6,004 (+6.3%); R&D Expense: 1,146 (-3.0%); SG&A Expense: 2,309 (+14.8%); Operating Income: 1,784 (+9.8%); Net Income: 1,190 (+7.8%); EPS: 0.91 (-1.1%).
    • Product Sales: Lantus: 1,567 (+8.1%); Plavix: 450 (+9.0%); Lovenox: 426 (+7.2%); Aprovel/Avapro: 178 (-14.8%); Cerezyme: 175 (+9.1%); Renvela/Renagel: 162 (-13.4%); Myozyme/Lumizyme: 138 (+9.4%); Fabrazyme: 116 (+21.9%); Aubagio: 112 (+156.8%); Apidra: 88 (+21.9%); Amaryl: 87 (-2.2%).
    • Vaccine Sales: Influenza: 650 (+15.0%); Polio/Pertussis/Hib: 259 (+7.4%); Meningitis/Pneumonia: 191 (-10.0%); Adult Booster: 131 (+54.8%); Other: 121 (+21.8%); Travel & Other Endemic: 99 (-3.0%).
    • 2014 Guidance: EPS growth: 6 - 8% (unch).
    | Comment!
  • Jul. 31, 2014, 11:31 AM
    • Sanofi (SNY +1.1%) (OTCQB:SNYNF +3.4%) Q2 results (€M): Total Sales: 8,075 (+0.9%), U.S. Sales: 2,569 (+9.4%), Western Europe: 1,908 (-2.8%), ROW: 743 (-11.2%); Gross Profit: 5,538 (+2.3%); Operating Income: 1,246 (+82.2%); Net Income: 804 (+63.4%); EPS: 0.59 (+73.5%); CF Ops: 3,471 (+7.1%).
    • 2014 Guidance: EPS growth: 6 - 8%.
    | Comment!
Visit Seeking Alpha's
SNYNF vs. ETF Alternatives
Company Description
Currently, there's no company description for SNYNF.
Sector: Healthcare
Country: France